Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA )

2.200 -0.060 (-2.65%)
Streaming Delayed Price Updated: 11:58 AM EDT, Oct 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,790,595
Open 2.180
Bid (Size) 2.180 (10)
Ask (Size) 2.270 (1)
Prev. Close 2.260
Today's Range 1.900 - 2.270
52wk Range 2.080 - 46.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. 
From ZyVersa Therapeutics
Via GlobeNewswire

Performance

YTD
-75.00%
-75.00%
1 Month
-7.56%
-7.56%
3 Month
-49.43%
-49.43%
6 Month
-62.23%
-62.23%
1 Year
-94.85%
-94.85%

More News

Read More
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
From ZyVersa Therapeutics
Via GlobeNewswire
Peering Into ZyVersa Therapeutics's Recent Short Interest
Via Benzinga
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
From ZyVersa Therapeutics
Via GlobeNewswire
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
Via AB Newswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
From ZyVersa Therapeutics
Via GlobeNewswire
ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
From ZyVersa Therapeutics
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
What's Going On With ZyVersa Stock?
Via Benzinga
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
Via Benzinga
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
From ZyVersa Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.